Arvinas (ARVN) EBITDA Margin (2017 - 2026)
Arvinas' (ARVN) quarterly EBITDA Margin came in at 408.97% in Q1 2026, down 44679.0% year-on-year from N/an in Q1 2025, and up 47.92% quarter-over-quarter from 785.26% in Q4 2025.
Arvinas (ARVN) EBITDA Margin (2017 - 2026) Analysis & Trends
Arvinas' EBITDA Margin history runs 10 years deep, the most recent figure standing at 408.97% for Q1 2026.
- On a quarterly basis, EBITDA Margin fell 44679.0% year-over-year to 408.97% in Q1 2026; TTM through Mar 2026 was 283.78%, a 26139.0% decrease from a year earlier, with the FY2025 full-year figure at 45.13%, up 4986.0% from the prior year.
- EBITDA Margin rose to 408.97% in Q1 2026 per ARVN's latest filing, from 785.26% in the prior quarter.
- Across five years, EBITDA Margin topped out at 383.53% in Q4 2023 and bottomed at 785.26% in Q4 2025.
- The 5-year median for EBITDA Margin is 194.67% (2022), against an average of 186.64%.
- Across the five-year window, EBITDA Margin soared 74896 bps in 2022 and sank 68695 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 200.0% in 2022, then jumped by 292 bps to 383.53% in 2023, then plunged by 126 bps to 98.31% in 2024, then tumbled by 699 bps to 785.26% in 2025, then soared by 48 bps to 408.97% in 2026.
- Per Business Quant, the three latest ARVN EBITDA Margin figures stand at 408.97% (Q1 2026), 785.26% (Q4 2025), and 104.53% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - | -408.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -408.97% |
| Dec 31, 2025 | -785.26% |
| Sep 30, 2025 | -104.53% |
| Jun 30, 2025 | -319.20% |
| Mar 31, 2025 | 37.82% |
| Dec 31, 2024 | -98.31% |
| Sep 30, 2024 | -58.89% |
| Jun 30, 2024 | -63.40% |
| Mar 31, 2024 | -329.25% |
| Dec 31, 2023 | 383.53% |
| Sep 30, 2023 | -213.58% |
| Jun 30, 2023 | -136.88% |
| Mar 31, 2023 | -269.85% |
| Dec 31, 2022 | -200.00% |
| Sep 30, 2022 | -193.67% |
| Jun 30, 2022 | -194.67% |
| Mar 31, 2022 | -217.74% |
| Dec 31, 2021 | -143.07% |
| Sep 30, 2021 | -508.60% |
| Jun 30, 2021 | -943.64% |